Stimuvax failure dents Merck Serono but freshens Oncothyreon

Merck Serono's (Merck KGaA) Phase III START trial investigating L-BLP25 (formerly Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) has failed to meet its primary endpoint.